Research progress of anti PD-1/PD-L1 immunotherapy biomarkers

Abstract

Abstract:Immunological checkpoint inhibitors of antiprogrammed cell death-1 and programmed cell death ligand-1 (PD-L1) have already demonstrated remarkable clinical efficacy for solid tumors, however, the effectiveness of single drug therapy in immunotherapy is not very high. Therefore, exploring the appropriate therapeutic predictive biomarkers so as to accurately identify the potential patients suitable for this therapy has become a research hotspot. Studies have shown that biomarkers such as PD-L1, tumor mutation burden and mismatch repair deficiency may be related to the efficacy of immunotherapy. Indepth analysis and exploration of these markers may provide a basis for determining those patients who are more likely to benefit from checkpoint inhibitor.

Key words:Immunotherapy,Biological markers,PD-1,PD-L1

Wang Huan, Jiang Haiping, Gao yuan, Xu Nong, Yu Xiongfei. Research progress of anti PD-1/PD-L1 immunotherapy biomarkers[J]. Journal of International Oncology, 2019, 46(1): 40-44.

References

［1］王巧红, 吴霞. 抗PD1/PDL1免疫治疗：筛选患者的生物标记物研究进展［J］. 中国免疫学杂志, 2017, 33(3): 457-463. DOI: 10.3969/j.issn.1000484X.2017.03.031. ［2］ Reck M, RodríguezAbreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PDL1positive nonsmallcell lung cancer［J］. N Engl J Med, 2016, 375(19): 1823-1833. DOI: 10.1056/NEJMoa1606774. ［3］ Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced nonsmallcell lung cancer: twoyear outcomes from two randomized, openlabel, phase Ⅲ trials (CheckMate 017 and CheckMate 057)［J］. J Clin Oncol, 2017, 35(35): 3924-3933. DOI: 10.1200/jco.2017.74.3602. ［4］赵沙, 蒋涛, 周彩存. 抗PD1/PDL1免疫治疗疗效预测标志物在非小细胞肺癌中的研究进展［J］. 肿瘤, 2016, 36(7): 823-828. DOI: 10.3781/j.issn.1000-7431.2016.55.175. ［5］ Voong KR, Feliciano J, Becker D, et al. Beyond PDL1 testingemerging biomarkers for immunotherapy in nonsmall cell lung cancer［J］. Ann Transl Med, 2017, 5(18): 376. DOI: 10.21037/atm.2017.06.48. ［6］ Johnson DB, Frampton GM, Rioth MJ, et al. Targeted next generation sequencing identifies markers of response to PD1 blockade［J］. Cancer Immunol Res, 2016, 4(11): 959-967. DOI: 10.1158/2326-6066.CIR-16-0143. ［7］ Kowanetz M, Zou W, Shames DS, et al. Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC［J］. Ann Oncol, 2016, 27 Suppl 6: vi15vi42. DOI:http://doi.org/10.1093/annonc/mdw363.25. ［8］ Peters S, Creelan B, Hellmann MD, et al. Impact of tumor mutation burden on the efficacy of firstline nivolumab in stage iv or recurrent nonsmall cell lung cancer: an exploratory analysis of CheckMate 026［J］. Cancer Res, 2017, 77(13 Suppl): CT082. DOI: 10.1158/15387445.AM2017CT082. ［9］朱涤潮, 张涛, 张明辉, 等. MMR/MSI在结直肠癌抗PD1/PDL1免疫检查点治疗中的作用［J］. 肿瘤学杂志, 2017, 23(10): 904-909. DOI: 10.11735/j.issn.1671170X.2017.10.B014. ［10］ Lee CK, Man J, Lord S, et al. Checkpoint inhibitors in metastatic EGFRmutated nonsmall cell lung cancer—a metaanalysis［J］. J Thorac Oncol, 2017, 12(2): 403-407. DOI: 10.1016/j.jtho.2016.10.007. ［11］ Chowell D, Morris LGT, Grigg CM, et al. Patient HLA class Ⅰ genotype influences cancer response to checkpoint blockade immunotherapy［J］. Science, 2018, 359(6375): 582-587. DOI: 10.1126/science.aao4572. ［12］ Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA4 blockade relies on the gut microbiota［J］. Science, 2015, 350(6264): 1079-1084. DOI: 10.1126/science.aad1329. ［13］王珊, 董丽儒, 任会强, 等. 肺腺癌中PD1、PDL1蛋白表达与KRAS基因突变状态的相关性分析［J］. 临床与实验病理学杂志, 2017, 33(7): 754-758. DOI: 10.13315/j.cnki.cjcep.2017.07.011. ［14］ Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated nonsmallcell lung cancer (POPLAR): a multicentre, openlabel, phase 2 randomised controlled trial［J］. Lancet, 2016, 387(10030): 1837-1846. DOI: 10.1016/S01406736(16)00587-0. ［15］ Hermitte F. Biomarkers immune monitoring technology primer: immunoscore colon［J］. J Immunother Cancer, 2016, 4: 57. DOI: 10.1186/s40425-016-0161-x. ［16］ Galon J, Mlecnik B, Marliot F, et al. Validation of the immunoscore (IM) as a prognostic marker in stage Ⅰ/Ⅱ/Ⅲ colon cancer: results of a worldwide consortiumbased analysis of 1,336 patients［J］. J Clin Oncol, 2016, 34 Suppl 15: 3500. DOI: 10.1200/JCO.2016.34.15_suppl.3500. ［17］ Donnem T, Hald SM, Paulsen EE, et al. Stromal CD8+ Tcell density—a promising supplement to TNM staging in nonsmall cell lung cancer［J］. Clin Cancer Res, 2015, 21(11): 2635-2643. DOI: 10.1158/10780432.CCR-14-1905. ［18］ Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance［J］. Nature, 2014, 515(7528): 568-571. DOI: 10.1038/nature13954. ［19］ Martens A, WistubaHamprecht K, Yuan J, et al. Increases in absolute lymphocytes and circulating CD4+ and CD8+ T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab［J］. Clin Cancer Res, 2016, 22(19): 4848-4858. DOI: 10.1158/10780432.CCR-16-0249. ［20］ Olugbile S, Kiyotani K, Inoue H, et al. P3.02c058 indepth molecular characterization of T cell clonal expansion induced by antiPD1 therapy in NSCLC［J］. J Thorac Oncol 2017, 12 (1 Suppl): S1310-S1311. DOI:https://doi.org/10.1016/j.jtho.2016.11.1853. ［21］ Sanmamed MF, PerezGracia JL, Schalper KA, et al. Changes in serum interleukin8 (IL8) levels reflect and predict response to antiPD1 treatment in melanoma and nonsmallcell lung cancer patients［J］. Ann Oncol, 2017, 28(8): 19881995. DOI: 10.1093/annonc/mdx190. ［22］ Lou Y, Diao L, Cuentas ER, et al. Epithelialmesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma［J］. Clin Cancer Res, 2016, 22(14): 3630-3642. DOI: 10.1158/1078-0432.CCR-15-1434. ［23］ Sivan A, Corrales L, Hubert N, et al. Commensal bifidobacterium promotes antitumor immunity and facilitates antiPDL1 efficacy［J］. Science, 2015, 350(6264): 1084-1089. DOI: 10.1126/science.aac4255. ［24］ Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1based immunotherapy against epithelial tumors［J］. Science, 2018, 359(6371): 91-97. DOI: 10.1126/science.aan3706. ［25］ Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to antiPD-1 immunotherapy in melanoma patients［J］. Science, 2018, 359(6371): 97-103. DOI: 10.1126/science.aan4236. ［26］ Voong KR, Feliciano J, Becker D, et al. Beyond PD-L1 testingemerging biomarkers for immunotherapy in nonsmall cell lung cancer［J］. Ann Transl Med, 2017, 5(18): 376. DOI: 10.21037/atm.2017.06.48.

[1]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[2]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[5]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong.Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(4): 210-216.
[6]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[7]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150.
[8]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180.
[9]	Cui Tenglu, Lyu lu, Sun Pengfei.Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma[J]. Journal of International Oncology, 2023, 50(9): 548-552.
[10]	Guo Ciliang, Jiang Chunping, Wu Junhua.Gut microbiome and tumor immunotherapy[J]. Journal of International Oncology, 2023, 50(7): 432-436.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Lyu Lu, Sun Pengfei.Gut flora and cervical cancer[J]. Journal of International Oncology, 2023, 50(6): 373-376.
[13]	Gu Anqin, Long Jinhua, Jin Feng.Clinical research progress of immunotherapy for nasopharyngeal carcinoma[J]. Journal of International Oncology, 2023, 50(5): 299-303.
[14]	Ding Hao, Ying Jintao, Fu Maoyong.Research progress of CAR-T in the treatment of esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2023, 50(4): 231-235.
[15]	Ma Pengcheng, Chen Yu.Research progress of primary pulmonary lymphoepithelioma-like carcinoma[J]. Journal of International Oncology, 2023, 50(3): 174-178.